Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Diamyd Medical

9.83 SEK

-0.30 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.30 %
-0.61 %
-9.98 %
+1.55 %
-39.93 %
-39.93 %
-31.75 %
-66.06 %
+227.37 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
1.35B SEK
Turnover
2.13M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/1
2026

Interim report Q1'26

25/3
2026

Interim report Q2'26

24/6
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release12/12/2025, 10:00 AM

Diamyd Medical AB: Diamyd Medical finalizing Phase 3 screening as GMP review progresses

Diamyd Medical
Regulatory press release12/12/2025, 10:00 AM

Diamyd Medical AB: Diamyd Medical slutför fas 3-screening och GMP-granskningen fortskrider

Diamyd Medical
Regulatory press release12/4/2025, 4:00 PM

Bulletin from Annual General Meeting of Diamyd Medical AB

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release12/4/2025, 4:00 PM

Kommuniké från årsstämma i Diamyd Medical AB

Diamyd Medical
Regulatory press release12/2/2025, 9:55 AM

Diamyd Medical AB: Annual Report 2024/2025

Diamyd Medical
Press release12/1/2025, 6:41 AM

BioStock: Lifs hållbarhetskonferens 2025 med fokus på omställning, konkurrenskraft och hållbar produktion

Diamyd Medical
Press release12/1/2025, 6:41 AM

BioStock: Lif's sustainability conference 2025 with a focus on transition, competitiveness and sustainable production

Diamyd Medical
Regulatory press release11/14/2025, 7:45 AM

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026

Diamyd Medical
Regulatory press release11/14/2025, 7:45 AM

Diamyd Medical AB: Diamyd Medicals fas 3-studie för typ 1-diabetes har passerat den sista säkerhetsgranskningen inför den tidiga resultatavläsningen i mars 2026

Diamyd Medical
Regulatory press release11/13/2025, 7:30 AM

Diamyd Medical AB: Årsredovisning 2024/2025

Diamyd Medical
Regulatory press release11/13/2025, 7:28 AM

Diamyd Medical AB: Information about the Annual Report 2024/2025

Diamyd Medical
Regulatory press release11/13/2025, 7:28 AM

Diamyd Medical AB: Information om Årsredovisning 2024/2025

Diamyd Medical
Regulatory press release11/12/2025, 11:45 AM

Diamyd Medical AB: Diamyd Medical uppmärksammar Världsdiabetesdagen med expertpanel om framtiden för behandling av typ 1-diabetes

Diamyd Medical
Regulatory press release11/12/2025, 11:45 AM

Diamyd Medical AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment

Diamyd Medical
Regulatory press release11/4/2025, 7:00 AM

Kallelse till årsstämma i Diamyd Medical AB

Diamyd Medical
Press release10/10/2025, 10:16 AM

BioStock: Screening kan ändra spelplanen för typ 1-diabetes

Diamyd Medical
Press release10/10/2025, 10:16 AM

BioStock: Screening - a potential game changer for type 1 diabetes

Diamyd Medical
Press release10/9/2025, 5:27 AM

DNB Carnegie Access: Diamyd Medical: Solid finish to the fiscal year

Diamyd Medical
Regulatory press release10/8/2025, 6:15 AM

Diamyd Medical AB: Bokslutskommuniké 24/25

Diamyd Medical
Regulatory press release10/8/2025, 6:15 AM

Diamyd Medical AB: Year-End Report 24/25

Diamyd Medical
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.